Form 4: Director Vincent Awarded 3,000 SeaStar Medical RSUs

SeaStar Medical Holding Corp. Director Bernadette N. Vincent received an award of 3,000 Restricted Stock Units, vesting fully on February 6, 2027.

Summary

• Bernadette N. Vincent, a Director of SeaStar Medical Holding Corp. (ICU), was granted 3,000 Restricted Stock Units (RSUs).
• The RSUs were awarded on February 6, 2026, at a price of $0 per unit, indicating an equity compensation grant.
• These RSUs are scheduled to vest in full on February 6, 2027.
• Following this transaction, Ms. Vincent beneficially owns 4,200 shares of Common Stock directly.
• Eric Schlorff, the Chief Executive Officer, has been granted Power of Attorney to sign Section 16 filings on behalf of Ms. Vincent.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued director engagement and alignment with long-term company performance through equity compensation.

Positives

• The RSU award aligns the director's long-term financial interests with those of the company's shareholders.
• The grant of RSUs is a common form of non-cash compensation for directors, indicating continued commitment to the company and its future performance.

Negatives

• No immediate cash inflow for the director from this award, as it is an RSU grant that vests in the future.
• There is a minor potential for dilution for existing shareholders upon the vesting of these RSUs, though typical for director compensation.

Risks

• The ultimate value of the RSU award to the director is contingent on the future performance of SeaStar Medical's stock price until the vesting date.
• No specific operational or financial risks are detailed in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing indicates a future vesting event on February 6, 2027, for the awarded RSUs, linking the director's future compensation to the company's performance and stock value.

Management Comments

• "The undersigned hereby constitutes and appoints Eric Schlorff, the Chief Executive Officer of SeaStar Medical Holding Corporation (the Company), signing singly, as his or her true and lawful attorney-in-fact..." (from Power of Attorney)

Industry Context

StockSavvy.ai notes that RSU awards are a standard practice in corporate compensation, particularly for directors, to foster long-term alignment with shareholder interests. This transaction reflects routine equity compensation rather than a significant strategic shift within the medical device or biotechnology industry.

Comparison to Industry Standards

• The grant of 3,000 RSUs to a director is a common practice in the biotechnology and medical device industry for companies of similar market capitalization to SeaStar Medical.
• Comparable companies often use RSUs as a key component of non-executive director compensation, typically vesting over one to three years, making the one-year vesting period for these RSUs within industry norms.
• For instance, directors at similar-stage biotech firms like Athersys, Inc. or Organogenesis Holdings Inc. frequently receive annual RSU grants ranging from 2,000 to 10,000 units, depending on board committee roles and overall compensation philosophy.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting, but generally positive as it aligns director incentives with shareholder interests.
• Management: Eric Schlorff (CEO) gains administrative authority for Section 16 filings for Ms. Vincent, streamlining compliance.

Next Steps

• The 3,000 RSUs granted to Bernadette N. Vincent are scheduled to vest in full on February 6, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine RSU award to a director, which is a standard compensation practice aimed at aligning interests. It does not contain information that would fundamentally alter the investment thesis for SeaStar Medical Holding Corp. Therefore, a "hold" recommendation is appropriate, as the filing provides no new material information to warrant a change in investment position.

Keywords

SeaStar Medical Holding Corp, ICU, Bernadette Vincent, Director, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation, Corporate Governance